Information Provided By: 
Fly News Breaks for April 14, 2016
HZNP
Apr 14, 2016 | 06:54 EDT
Brean Capital analyst Difei Yang noted that while Horizon Pharma provided softer guidance for 1H sales, the company also reaffirmed its full year guidance. However, the analyst believes Horizon may miss its guidance as payor push-back on Duexis and Vimovo may create a gap too wide to bridge by other growing assets. She keeps a Buy rating on Horizon, though, as she thinks the stock has more than priced in any additional downside. Yang trimmed her price target on the stock to $30 from $32.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
